Friday, September 15, 2017 3:35:55 PM
And it's still ridiculously undervalued here, as we all know.
Even if for some unexpected reason the co. came in with only EPS of, say, 0.07 for the Q4, due to some one-time expense or expenses, that would make for a great trailing year EPS of 0.40, and the stock would imo still merit a P/E of at least 15-20, if not much higher since it has a "best in sector" balance sheet and all these growth prospects with the new partnerships.
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • ELAB • Mar 18, 2024 8:51 AM
Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • PEI • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM